Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study DOI Creative Commons
Kazuaki Chayama,

Cara Ng,

Isabella Brohman

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0319010 - e0319010

Published: Feb. 28, 2025

Background People living with HIV (PLHIV) who use drugs face overlapping social-structural inequities that contribute to suboptimal adherence antiretroviral therapy (ART). Recent research suggests long-acting (LA-ART) can offer an important alternative daily oral ART by mitigating barriers, but this work has largely excluded PLHIV drugs. We, therefore, explored the acceptability of injectable and transdermal LA-ART among in Canada, which no-cost universal access ART. Greater understanding drugs’ perspectives on will be essential fully leverage treatment advances maximize its individual- population-level benefits. Methods From February 2019 2020, we conducted in-depth interviews 33 Vancouver, Canada (i.e., ≦ 50%). Participants were recruited for through a prospective cohort study. Interviews audio-recorded, transcribed, analyzed using inductive deductive approaches. Results Our analysis identified key factors shaping acceptability. First, enthusiasm was highest participants less satisfied regimens due pill burden or adverse side effects struggled substance (e.g., homelessness, incarceration). Moreover, had physicians they trusted their as credible sources information LA-ART, indicated desire informed shared decision-making regarding changes. Finally, emphasized there is no one-size-fits-all approach highlighted importance full range available options, including LA-ART. Conclusions There potential high uptake drugs, particularly those experience barriers structural vulnerability. While our findings are limited specific population setting, nevertheless underscore need efforts ensure equitable

Language: Английский

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples DOI Creative Commons
Aleksandr Ianevski,

Anil K Giri,

Tero Aittokallio

et al.

Nucleic Acids Research, Journal Year: 2022, Volume and Issue: 50(W1), P. W739 - W743

Published: April 29, 2022

SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, has become popular tool multi-dose data analytics, partly because the development functionality graphical interface been driven by diverse user community, including both chemical biologists computational scientists. Here, we describe latest upgrade this community-effort, 3.0, introducing number novel features that support multi-sample synergy, consensus synergy score combines multiple scoring models, an improved outlier detection eliminates false positive results, along with many other post-analysis options such as weighting drug concentrations distinguishing between different modes (potency efficacy). Based on requests, several additional improvements were also implemented, new visualizations export combinations. With these improvements, 3.0 supports robust identification consistent combinatorial synergies discovery clinical translation.

Language: Английский

Citations

385
Long-acting antiretrovirals and HIV treatment adherence DOI Creative Commons
Jean B. Nachega, Kimberly K. Scarsi, Monica Gandhi

et al.

The Lancet HIV, Journal Year: 2023, Volume and Issue: 10(5), P. e332 - e342

Published: April 14, 2023

Language: Английский

Citations

49
Long-acting parenteral drug delivery systems for the treatment of chronic diseases DOI
Anil B. Jindal,

Atharva R. Bhide,

Sagar Salave

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 198, P. 114862 - 114862

Published: May 7, 2023

Language: Английский

Citations

47
Development of dissolving microneedles for intradermal delivery of the long-acting antiretroviral drug bictegravir DOI Creative Commons

Chunyang Zhang,

Lalitkumar K. Vora, Ismaiel A. Tekko

et al.

International Journal of Pharmaceutics, Journal Year: 2023, Volume and Issue: 642, P. 123108 - 123108

Published: June 8, 2023

Oral administration and intramuscular (IM) injection are commonly recommended options for human immunodeficiency virus (HIV) treatment. However, poor patient compliance due to daily oral dosing, pain at sites the demand trained healthcare staff injections limit success of these routes, especially in low-resource settings. To overcome limitations, first time, we propose novel bilayer dissolving microneedles (MNs) intradermal delivery long-acting nanosuspensions antiretroviral (ARV) drug bictegravir (BIC) potential HIV treatment prevention. The BIC were prepared using a wet media milling technique on laboratory scale with particle size 358.99 ± 18.53 nm. loading nanosuspension-loaded MNs powder-loaded 1.87 mg/0.5 cm2 2.16 cm2, respectively. Both exhibited favorable mechanical insertion ability skin simulant Parafilm® M excised neonatal porcine skin. Importantly, pharmacokinetic profiles Sprague Dawley rats demonstrated that able intradermally deliver 31% from form depots. After single application, both coarse achieved sustained release, maintaining plasma concentrations above therapeutic levels (162 ng/mL) 4 weeks. These minimally invasive potentially self-administered could improve compliance, providing promising platform nanoformulated ARVs resulting prolonged particularly patients

Language: Английский

Citations

42
Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis DOI Creative Commons
Gert-Jan Wijnant, Franck Dumetz, Laura Dirkx

et al.

Frontiers in Tropical Diseases, Journal Year: 2022, Volume and Issue: 3

Published: May 12, 2022

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite. The transmitted female sand flies and, depending on infecting parasite species, causes either cutaneous (stigmatizing skin lesions), mucocutaneous (destruction of mucous membranes nose, mouth and throat) or visceral (a potentially fatal infection liver, spleen bone marrow). Although more than 1 million new cases occur annually, chemotherapeutic options are limited their efficacy jeopardized increasing treatment failure rates growing drug resistance. To delay emergence resistance to existing drugs, elucidating currently unknown variable (related susceptibility, host immunity pharmacokinetics) improved use genotypic phenotypic tools define, measure monitor in field critical. This review highlights recent progress our understanding action , ongoing challenges (including setbacks related COVID-19 pandemic) provides an overview possible strategies tackle this public health challenge.

Language: Английский

Citations

42
A brief history and future prospects of contraception DOI
Deborah J. Anderson, Daniel St Johnston

Science, Journal Year: 2023, Volume and Issue: 380(6641), P. 154 - 158

Published: April 13, 2023

Modern contraception ushered in an era of improved family planning, but more than 60 years after approval "the pill," product gaps and unmet needs still exist. Nearly 250 million women worldwide who want to delay or avoid pregnancy do so ineffectively not at all, the principal mechanism male contraception, condoms, has changed 100 years. As a result, about half pregnancies that occur globally each year are unintended. Increasing contraceptive options uptake will curtail abortions, empower men, promote healthy families, moderate population growth overtaxes environment. This Review addresses history shortcomings methods, promising approaches for female simultaneous protection against unintended sexually transmitted infections.

Language: Английский

Citations

23
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study DOI

Joseph J. Eron,

Susan J. Little,

Gordon Crofoot

et al.

The Lancet HIV, Journal Year: 2024, Volume and Issue: 11(3), P. e146 - e155

Published: Jan. 30, 2024

Language: Английский

Citations

16
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter DOI Creative Commons

Miruna-Maria Apetroaei,

Bruno Ștefan Velescu, Marina Ionela Nedea

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(4), P. 915 - 915

Published: April 20, 2024

Human immunodeficiency virus (HIV) is a significant global health issue that affects substantial number of individuals across the globe, with total 39 million living HIV/AIDS. ART has resulted in reduction HIV-related mortality. Nevertheless, medication resistance obstacle management The unique genetic composition HIV enables it to undergo rapid mutations and adapt, leading emergence drug-resistant forms. development drug can be attributed various circumstances, including noncompliance treatment regimens, insufficient dosage, interactions between drugs, viral mutations, preexposure prophylactics, transmission from mother child. It therefore essential comprehend molecular components mechanisms antiretroviral medications devise efficacious options for

Language: Английский

Citations

9
Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa DOI Creative Commons
Deborah Ekusai-Sebatta,

Ritah Shanice Namugenyi,

Eva Laker

et al.

International Health, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Abstract Background This article discusses the ethical issues surrounding integration of long-acting injectable antiretroviral therapy (LA-ART) in programmatic management human immunodeficiency virus (HIV). As medical landscape evolves, implementing LA-ART introduces many that should be considered for success scale-up diverse settings. Methods examines key such as bioethical concerns around rollout LA-ART, including regulatory requirements, a person's autonomy, informed consent, privacy and confidentiality; societal implications providing impact on stigma discrimination; ethics who receives financial accessibility, equitable access, inclusive decision-making cultural sensitivity; an expensive intervention, cost-effectiveness, supply chain sustainability resource allocation. By critically analysing issues, we aim to guide policymakers identify areas further research. Conclusion Our overarching is ensure rights people living with HIV are protected implementors plan focus eastern southern Africa. The utilization resource-limited settings poses significant challenges, necessitating careful consideration access equity, stigma, discrimination, treatment adherence.

Language: Английский

Citations

1
Lipid based intramuscular long-acting injectables: Current state of the art DOI Creative Commons
Janine M. Wilkinson,

Damilola Ajulo,

Valeria Tamburrini

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2022, Volume and Issue: 178, P. 106253 - 106253

Published: July 3, 2022

Long acting injectables (LAI) have received increased research and commercial interest due to their potential for improving treatment effectiveness adherence antipsychotic, antiviral addiction treatments. A range of materials been used formulate LAI products, including lipids polymers. Classic lipid-based LAI, such as oil solutions antipsychotic drugs, widely prescribed patients. Clinical evidence has shown significantly improved key therapeutic markers reduction relapses in the case schizophrenia The products can be given either via subcutaneous or intramuscular injection. main types formulations include solutions, nanoparticles lipid based liquid crystal formulations, which are currently clinically available, suspensions oleogels no available. This review will discuss all relevant aspects related development long with a special focus on (IM) injectables. It aims provide useful guidance effective future product design development. Lipid-based nanoformulations not discussed this they thoroughly reviewed literature elsewhere.

Language: Английский

Citations

36